Want to see INMB full AI Analyst Report?
INMB Stock Chart & Stats
$2.43
$0.11(6.79%)
At close: 4:00 PM EDT
$2.43
$0.11(6.79%)
Day’s Range― - ―
52-Week Range$1.09 - $2.60
Previous Close$1.86
Volume180.53K
Average Volume (3M)311.90K
Market Cap
$52.45M
Enterprise Value$26.55M
Total Cash (Recent Filing)$18.41M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 04, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding27,753,790
10 Day Avg. Volume256,864
30 Day Avg. Volume311,898
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.76
Price to Sales (P/S)829.46
P/FCF Ratio-1.76
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-245.79
Enterprise Value/Ebitda-1.46
Forecast
1Y Price Target
$8.00Price Target Upside229.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory PathwayFormal MHRA alignment and an approved pediatric investigation plan reduce uncertainty around the Ebstracel regulatory pathway. The planned UK, European and U.S. submissions create defined milestones that can support development progress and potential commercialization over the next several quarters.
Manufacturing ReadinessProgress toward commercial-compliant processing and transfer of MSC isolation to the intended facility indicates that manufacturing execution is advancing alongside clinical and regulatory work. This can improve filing readiness and support future supply planning if approvals are obtained.
XPro Clinical ProgressFDA Fast Track status and statistically significant Phase 2 imaging results strengthen the development profile of XPro in early Alzheimer's disease. The findings provide clinical support for continued advancement and broaden the company’s potential value beyond its rare-disease program.
Bears Say
Pre-commercial LossesINMB has not established product revenue and continues to report substantial losses, leaving financial performance dependent on development progress rather than operating sales. This weak earnings base limits internally generated funding and makes future results highly milestone-driven.
Cash Runway And FundingPersistent operating and free-cash-flow deficits mean the company must continue consuming capital to advance its programs. Even with management’s projected runway into Q2 2027, additional financing may be required thereafter, creating ongoing funding and potential dilution pressure.
Rebate-dependent ResultsThe sharp improvement in quarterly reported results was aided by a nonrecurring R&D rebate rather than a durable change in the underlying commercial model. As that benefit fades, reported expenses and losses may rise, making financial progress appear less consistent.
Inmune Bio News
INMB FAQ
What was Inmune Bio Inc’s price range in the past 12 months?
Inmune Bio Inc lowest stock price was $1.09 and its highest was $2.60 in the past 12 months.
What is Inmune Bio Inc’s market cap?
Inmune Bio Inc’s market cap is $52.45M.
When is Inmune Bio Inc’s upcoming earnings report date?
Inmune Bio Inc’s upcoming earnings report date is Nov 04, 2026 which is in 23 days.
How were Inmune Bio Inc’s earnings last quarter?
Inmune Bio Inc released its earnings results on Aug 06, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.207 by $0.157.
Is Inmune Bio Inc overvalued?
According to Wall Street analysts Inmune Bio Inc’s price is currently Undervalued.
Does Inmune Bio Inc pay dividends?
Inmune Bio Inc does not currently pay dividends.
What is Inmune Bio Inc’s EPS estimate?
Inmune Bio Inc’s EPS estimate is -0.15.
How many shares outstanding does Inmune Bio Inc have?
Inmune Bio Inc has 27,753,790 shares outstanding.
What happened to Inmune Bio Inc’s price movement after its last earnings report?
Inmune Bio Inc reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.207. Following the earnings report the stock price went up 9.162%.
Which hedge fund is a major shareholder of Inmune Bio Inc?
Currently, no hedge funds are holding shares in INMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inmune Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (229.22% Upside)
$8.00 (229.22% Upside)
Blogger Sentiment
Bullish
INMB Sentiment 100%
Sector Average 67%
Sector Average 67%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.8%
Last 30 Days ▲ 22.7%
Last 30 Days ▲ 22.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.54%
12-Months-Change
Fundamentals
Return on Equity
-82.87%
Trailing 12-Months
Asset Growth
-26.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inmune Bio Inc
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
INMB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong program‑level de‑risking and tangible operational progress: formal MHRA alignment, pediatric plan approval, manufacturing readiness for Ebstracel, strengthened IP and SAB, and encouraging XPro Phase 2 imaging results with FDA Fast Track designation. Financially the quarter showed a large improvement in reported loss driven by nonrecurring items and R&D rebates, and management is controlling burn. Major near‑term milestones (UK MAA submission, EMA and US filings) are well defined. Principal concerns are a limited cash runway into Q2 2027, reliance on one‑time rebates, enrollment pace for the confirmatory trial, and financing/valuation uncertainty that could lead to dilution. On balance, the operational and clinical accomplishments outweigh the financial timing risks, but successful execution of filings and financing will be critical.View all INMB earnings summariesINMB Stock 12 Month Forecast
Average Price Target
$8.00
▲(229.22% Upside)
Technical Analysis
Veru
―
Karyopharm Therapeutics
―
Cue Biopharma
―
Celularity
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
10.81% Insiders
4.70% Mutual Funds
0.62% Other Institutional Investors
81.11% Public Companies and
Individual Investors